216 results about "Lysine" patented technology

This invention belongs to the field of diagnostic testing technology. Addressing the problem that existing gestational diabetes screening methods may miss the optimal time for early intervention, leading to the failure to promptly detect and manage some potentially hyperglycemic pregnant women, increasing the risk of adverse maternal and fetal outcomes, this invention proposes a plasma metabolic biomarker for the early diagnosis or prediction of gestational diabetes and its application. This plasma metabolic biomarker is at least one of L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine-deoxycholic acid. The five plasma metabolic biomarkers provided by this invention can be applied to the early diagnosis or prediction of gestational diabetes, and are of great significance for the prevention or treatment of gestational diabetes.

The application relates to the technical field of beef cattle breeding, and particularly discloses a compound preparation for promoting the feed intake, daily weight gain and improving the meat quality of beef cattle and application thereof, which is prepared from the following components in percentage by volume: 40% of micro-ecological preparation, 30% of hawthorn, 10% of medicated leaven, 10% of malt, 5% of areca nut and 5% of dried tangerine or orange peel; the compound preparation is prepared from microorganisms and multiple natural Chinese herbal medicines in a specific and scientific matching ratio; experiments prove that the compound preparation can increase the feed intake of beef cattle by 11.33%, increase the daily weight gain by 16.16%, and significantly shorten the breeding cycle; meanwhile, the contents of aspartic acid, threonine, glutamic acid, alanine, valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, arginine and proline in the muscle are significantly increased, the nutritional quality and flavor taste of beef are effectively improved, the preparation is natural, residue-free and side-effect-free, the preparation method is simple, the cost is low, and the preparation has extremely high practical value and popularization prospect.

This invention relates to the fields of bioengineering and fermentation engineering, and discloses a genetically engineered *Streptomyces albopictus* strain that produces high levels of ε-polylysine and its fermentation production process. This genetically engineered strain uses *Streptomyces albopictus* strains acclimated to ε-polylysine tolerance as a chassis, and its genome integrates... ppc and dapf Through expression box, heterogeneous asd Expression cassettes, containing secretory signal peptides lysp Fusion expression cassettes and D404A / K499A point mutations pls Expression cassette. The fermentation process employs a two-stage pH control strategy, maintaining a neutral environment during the cell growth phase and adjusting to an acidic environment during product synthesis. This invention improves ε-polylysine yield through a synergistic strategy of enhancing precursor supply, constructing efflux detoxification channels, and increasing synthase activity; combined with an acidic fermentation process, it effectively inhibits product degradation, yielding a high-molecular-weight and highly uniform target product suitable for industrial production.

The application provides an arginine mutant and application thereof in 1,4-butanediamine biosynthesis, and belongs to the field of bioengineering. Escherichia coli The mutant is obtained by site-directed mutagenesis of key site amino acid residues based on wild-type EcAdiA from strain The application improves the enzyme activity stability of arginine decarboxylase in neutral environment, improves the conversion rate and conversion speed of 1,4-butanediamine in neutral environment, and lays a foundation for high-efficiency biosynthesis of 1,4-butanediamine.

The present application relates to a kind of environment-friendly water-based phenolic resin anticorrosive coating and its preparation process, belong to the field of coating technology.The coating is made of water-based phenolic resin emulsion, hyaluronic acid-lysine composition load nano SiO2-ZnO composite filler, synergistic anticorrosive filler, wetting dispersant, film forming aid, leveling thickener, defoaming agent and deionized water.The superhydrophilic of hyaluronic acid fundamentally solves the dispersion and storage stability problem of phenolic resin in aqueous phase, and the amino group of its lysine side chain can also chemically bond with resin during curing, significantly enhancing the adhesion, flexibility and interfacial bonding strength of coating.At the same time, nano SiO2, ZnO and synergistic anticorrosive filler construct a multiple synergistic anticorrosive network of physical shielding, sacrificial anode and chemical passivation, achieving long-term active protection.The whole system uses water as medium, selects bio-based raw materials and low VOC additives, and the environmental protection is outstanding.

This invention relates to the field of feed processing technology and discloses a compound nutritional feed premix and its preparation method. By total mass percentage, it comprises the following components: 52.60%–54.60% jujube powder, 17.50%–18.30% lard and tile powder, 23.20%–24.10% wheat bran, 0.25%–0.40% edible salt, 0.40%–0.60% compound vitamins, 1.10%–1.30% compound trace elements, 0.80%–1.00% lysine, 1.10%–1.30% montmorillonite, and 0.15%–0.20% compound enzyme preparation. By using pitted Xinjiang jujube powder and fresh lard and tile powder as core raw materials, combined with wheat bran, edible salt, compound vitamins, compound trace elements, lysine, and montmorillonite with a blue absorption capacity of 42, the premix achieves nutritional complementarity among various raw materials and improves the palatability and overall nutritional value of the feed.

The present invention discloses a method for producing perillaldehyde and / or perillyl lactone, comprising: contacting a first component with a second component to produce perillaldehyde and / or perillyl lactone; wherein the first component is selected from components containing lysine-2-diol, and the second component is selected from enzymes or microorganisms or their cell lysates or enzyme extracts capable of converting lysine-2-diol into perillaldehyde and / or perillyl lactone.

The invention relates to methods and compositions for preventing or treating a neuropathology in a subject associated with or induced or caused by a P. gingivalis infection, preventing the deposition of or reducing the level of P. gingivalis gingipain in neuronal tissue, delaying the onset of a P. gingivalis-induced or associated neuropathology, for preventing or slowing the rate of abnormal protein deposition in the neuronal tissue, and / or reducing neuroinflammation, the methods comprising administering an RNA polynucleotide encoding a protein comprising or consisting of: - one or more amino acid sequences of an active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and / or - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, wherein the polynucleotide is capable of being translated in a mammalian cell.

The application belongs to the technical field of biological medicine, and particularly relates to application of an inhibitor for inhibiting lactic acid modification of lysine at the 249th position of HSP60 protein. The application provides application of the inhibitor for inhibiting lactic acid modification of lysine at the 249th position of HSP60 protein in preparation of a medicine for preventing and / or treating psoriasis, and an amino acid sequence of the HSP60 protein (heat shock protein 60) is shown as SEQ ID NO. 1. The application provides a brand-new, mechanism-driven psoriasis treatment target, lactic acid modification of lysine at the 249th position of HSP60 protein. By inhibiting the specific modification, the purpose of precise intervention and treatment from an upstream of the disease is achieved by stabilizing mitochondrial function and blocking intrinsic immune activation triggered by metabolic stress.

The present invention provides a high-protein bio-fermented aquatic feed and a preparation method thereof. The aquatic feed comprises the following raw materials in parts by weight: 20-30 parts of imported fish meal, 10-15 parts of compound minerals, 5-10 parts of bioactive peptides, 5-10 parts of lysine, 5-10 parts of compound trace elements, 3-8 parts of compound vitamins, 3-6 parts of herbal extracts, 2-5 parts of compound probiotics, 2-4 parts of immune polysaccharides, and 1-3 parts of compound enzymes; the herbal extracts are prepared by fermenting astragalus membranaceus, isatis root, liquorice root, calotropis gigantea, ventilago leiocarpa benth, clove, rhizoma chuanxiong, and galangal officinale. By organically integrating imported fish meal, astaxanthin-peptide chelate, herbal extracts, compound immune polysaccharides, compound probiotics and various nutrients, the present invention realizes the synergistic effect of "promoting feeding - enhancing digestion - strengthening liver and gall - enhancing immunity - resisting stress - inhibiting bacteria - stabilizing water quality", significantly improves the growth rate, survival rate and comprehensive breeding benefit of crustacean aquatic animals, and has good economic value and application prospect.

The application discloses a method for preparing goldfish feed from fermented abalone viscera powder, and comprises the following steps: preparing fermented abalone viscera powder, including raw material pretreatment, strain activation, anaerobic fermentation and final treatment; preparing a formula of the goldfish feed, including fermented abalone viscera powder, spirulina powder, fish meal, soybean meal, rice bran, wheat flour, fish oil, alpha-starch, soybean lecithin, calcium dihydrogen phosphate, vitamin premix, mineral premix, betaine, garlicin, VC-phosphate, lysine and choline chloride; and preparing the goldfish feed, including accurate batching, uniform mixing, moisture adjustment and molding, grading granulation, drying and cooling and grading screening. The fermentation and feed preparation process is simplified, the complicated enzymolysis-fermentation combined process is abandoned, no professional technical personnel are needed, and the household breeders can prepare the feed through simple equipment, and the enterprises can mass-produce the feed; the formula is optimized for goldfishes in different growth stages, is suitable for multiple goldfishes such as golden goldfish and grass goldfish, and has high application flexibility.

The application discloses a kind of small molecule compound combination and the method for preparing vascular endothelial cell using the small molecule compound combination induced differentiation cell.The method is directed to induce differentiated cell, and finally prepare vascular endothelial cell;The directional induction includes inhibiting the activity of lysine deacetylase, inhibiting the signal path of TGF-β, inhibiting the activity of DNA methyltransferase (DNMT), activating the signal path of WNT / β-catenin and activating the signal path of cAMP.The present application can be converted into vascular endothelial cell by small molecule compound combination induction, and each step can realize accurate quality control, which is convenient for standardized operation and large-scale production.The method provided by the present application has wide donor sources, and the patient himself can be used as a donor, so that the vascular endothelial cells required for basic research, clinical treatment or tissue engineering production can be obtained in a short time.

The application discloses a kind of genetic engineering escherichia coli plasmid expression culture medium and fermentation process, including basic medium and feed medium;The basic medium includes glycerol, yeast hydrolysate, yeast peptone, L-glutamic acid, L-valine, L-isoleucine, arginine, tyrosine, lysine, proline, glycine, ammonium sulfate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, citric acid, magnesium sulfate, ferrous sulfate, zinc sulfate, calcium chloride, manganese chloride, cobalt chloride, copper chloride, sodium ethylenediaminetetraacetate;Feed medium includes glycerol, citric acid, magnesium sulfate, ferrous sulfate, zinc sulfate, calcium chloride, manganese chloride, cobalt chloride, copper chloride, sodium ethylenediaminetetraacetate.The application inhibits the accumulation of harmful metabolites, and creates the optimal intracellular environment for stable replication of plasmid.In industrial fermentation scale, the amount of plasmid harvested per liter of fermentation broth is more than 1 gram, and the supercoiling ratio of plasmid DNA is stably maintained at more than 90%, with minimal batch-to-batch variation.

The application belongs to the technical field of biomedical optical imaging, and more particularly relates to a biosafe skin optical clearing agent and method based on a lysine synergistic system. The biosafe skin optical clearing agent provided in the application contains lysine or a salt thereof as an active ingredient, can effectively reduce the light scattering of skin tissue, and thus realizes the optical clearing of skin, and meanwhile, the morphology of the skin tissue is well maintained during the treatment. The skin optical clearing agent has the advantages of simple active ingredient, high biosafety, remarkable skin optical clearing effect, convenient preparation, simple application operation and the like, and is suitable for the optical clearing treatment of ex vivo skin and in vivo skin.

The invention relates to a tetrapeptide of formula N-Palmitoyl-Lys-Thr-Phe-Lys, for use in the prevention and / or treatment of human atopic dermatitis (AD), as well as to a composition comprising at least said tetrapeptide and at least one physiologically acceptable excipient, for use in the prevention and / or treatment of human atopic dermatitis (AD).

This application provides a method for preparing pH-responsive polyamino acid drug-loaded nanoparticles based on sarcosine and their application. Sar-NNCA, L-lysine-NCA, and L-phenylalanine-NCA are dissolved in anhydrous DMF and polymerized under argon protection with a hexamethyldisilazine initiator to obtain a polyamino acid block copolymer Sar-NNCA. 80 -Lys(Cbz) n -Phe 10 The crude product was deprotected under HBr / acetic acid and loaded with DOX to obtain Sar. 80 -Lys n -Phe 10 -DOX. This application describes the preparation of a pH-responsive polymer nanoplatform, Sar, by encapsulating doxorubicin in polysarcosine-polylysine-polyphenylalanine nanoparticles via Schiff base bonds. 80 -Lys n -Phe 10 -DOX is used for tumor treatment. These polyamino acid nanoparticles are spherical with an average particle size of approximately 200 nanometers, exhibiting pH-responsive properties, excellent cellular uptake capacity, and anti-tumor effects. In vitro experiments show that Sar... 80 -Lys n -Phe 10 The carrier material exhibits excellent biocompatibility. The newly synthesized Sar... 80 -Lys n -Phe 10 -DOX nanomicelles show promise as a drug delivery system for cancer treatment.

Provided is the use of a cell death-related protein in preparing L-lysine. Further provided is a bacterial strain capable of reducing toxic substances or eliminating foams during a fermentation process, so as to produce L-lysine with a high yield. In order to solve the technical problem, the described use is the use of a protein, or a substance for regulating the expression of a coding gene of the protein, or a substance for regulating the activity or content of the protein, in preparing L-lysine or improving the yield of L-lysine, the protein being specifically one or more of SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 7, SEQ ID No. 10 and SEQ ID No. 12. Experiments prove that knocking out the coding gene of the described protein helps to improve the yield of L-lysine in the bacterial strain.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

The present application relates to a kind of lysine beta-hydroxybutyryl site prediction method based on multi-source feature and three branch fusion network.It solves the problem of limited representation ability,generalization instability and insufficient explicit prior utilization caused by single feature source or single network structure in the prior art.It includes S1, data acquisition and sample construction;S2, sequence word encoding and position encoding;S3, residue physicochemical property matrix construction and joint representation;S4, engineering statistics feature extraction;S5, three branch feature learning;S6, fusion discrimination and output;S7, training and evaluation.The present application has the advantages that it meets the needs of rapid screening and priority ordering of potential Kbhb modification sites in protein sequence, and accurately and stably identifies candidate sites without relying on three-dimensional structure input.

The present invention is directed to a therapeutic agent for use in the treatment of a disease associated with gain-of-function of androgen receptor (AR) and / or with overexpression of an AR coactivator, such as Kennedy disease or cancer. The therapeutic agent of the invention comprises at least one inhibitor of an androgen receptor (AR) coactivator, selected from protein arginine methyltransferase 6 (PRMT6) inhibitor, lysine specific demethylase 1 (LSD1) inhibitor, or combinations thereof.

Provided is a cyclic peptide, which has a sequence of cyclo(X1X2X3X4X5X6), wherein X1 is asparagine; X2 is glycine or sarcosine; X3 is arginine; X4 is selected from a group consisting of threonine, tyrosine, and phenylalanine; X5 is lysine; and X6 is selected from a group consisting of tyrosine, valine, and glutamic acid. Provided is a preparation method for the cyclic peptide. Provided is a complex, comprising the cyclic peptide, a linker, and a chelating agent. Provided is a use of the complex as a radionuclide-labeled targeting molecule. Provided is a radionuclide labeling method, comprising bringing a complex that chelates a radionuclide into contact with an object to be labeled by the radionuclide.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for distinguishing hypertrophic cardiomyopathy and left ventricular hypertrophy and application. The application analyzes the metabolome of hypertrophic cardiomyopathy (HCM) patients, left ventricular hypertrophy (LVH) patients caused by non-hypertrophic cardiomyopathy and healthy people, finds that carnitine C16:2, carnitine C14:0, carnitine C16:0, carnitine C18:0 and carnitine C18:1 are differentially expressed in HCM patients and LVH patients, pyridoxine phosphate, ito acid, adenosine monophosphate, adenosine diphosphate and adenosine triphosphate are differentially expressed in HCM patients and healthy people, lysine base, methyl glutamic acid, acetyl proline, malate semialdehyde and citramalate are differentially expressed in LVH patients and healthy people, and ROC curve analysis shows excellent prediction effect, strong specificity and high sensitivity.

The present application belongs to the technical field of feed, and particularly relates to a broiler feed with reduced soybean meal dosage. The broiler feed with reduced soybean meal dosage comprises fermented distillers grains (FDG) with a mass fraction of 5% to 10%, and a residual basic daily ration; the basic daily ration comprises the following components in percentage by mass: corn 58.88%; soybean meal 31.50%; soybean oil 5.00%; stone powder 1.30%; salt 0.30%; calcium hydrogen phosphate 1.97%; DL-lysine 0.30%; DL-methionine 0.25%; premix 0.50%. It is found that fermentation can improve the feed nutritional value and apparent digestibility of distillers grains, and increase the addition amount of distillers grains in broilers; and when the addition amount reaches 10%, the liver and kidney functions, antioxidant capacity and digestive enzyme activity of the broilers are not obviously affected.

The present application discloses an antimicrobial nylon material, along with its preparation method and application. The present application relates to the technical field of antimicrobial polymer materials and addresses the limitations of existing antimicrobial nylon 6, particularly its insufficient antimicrobial efficacy and challenges in scalability for industrial production. In the present application, a seven-membered cyclic lysine-derived monomer is copolymerized with a lactam via hydrolytic copolymerization using water as an initiator, yielding a copolyamide. The resulting copolyamide is then subjected to a protonation reaction through heating and stirring in an acidic solution, followed by purification to obtain the final antimicrobial nylon material. The seven-membered cyclic lysine-derived monomer may be an unprotected cyclic lysine monomer, a mono-protected cyclic lysine monomer, or a salt form cyclic lysine monomer. The present invention exhibits broad applicability in antimicrobial-sensitive fields such as textiles, plates, pipes, packages or panels.

This application relates to a method for producing cadaverine dicarboxylate (cadaverine verphosphate or cadaverine azelaate), comprising a first step of culturing L-lysine-producing microorganisms in a medium supplemented with dicarboxylic acid in the form of diammonium dicarboxylate to obtain lysine dicarboxylate, and a second step of converting lysine dicarboxylate to cadaverine dicarboxylate. According to this application, by carrying out the process according to the above procedure, high-purity cadaverine dicarboxylate (cadaverine verphosphate or cadaverine azelaate) can be obtained without ion resin exchange, decarboxylation, and distillation steps.

The application discloses a preparation method of a material for an electronic product shell and relates to the technical field of polymer preparation, and the preparation method comprises the following steps: 1) Boc-polyamide acid prepolymer preparation; 2) compounding and foaming; and 3) forming and stepwise curing crosslinking. By introducing Boc-lysine and fluorine-containing monomers, the application overcomes the bottleneck of difficult solubility and processing of polyimide, and realizes high solid content processing and foaming. A unique physical and chemical synergistic foaming mechanism and a fiber interface chemical bonding technology are designed and adopted, and a composite material with the characteristics of ultralight weight, high strength, 200 DEG C high-temperature resistance, intrinsic flame retardance and ultralow dielectric constant is successfully prepared.

This invention discloses the application of L-lysine in improving the sensitivity of Vibrio alginolyticus to clindamycin. This invention discovers that the combined use of L-lysine and clindamycin can significantly increase reactive oxygen species within Vibrio alginolyticus, thereby increasing the amount of clindamycin entering the bacteria and ultimately leading to bacterial death. Therefore, L-lysine can improve bacterial sensitivity to clindamycin, thus overcoming the problem of bacterial resistance. The small molecule metabolite provided by this invention, when used in combination with clindamycin, can significantly enhance the bactericidal effect of clindamycin, exhibiting better efficacy, higher safety, and greater operability compared to existing methods that use clindamycin alone as an antibacterial drug.

The present invention relates to compositions comprising RNA, preferably messenger RNA (mRNA), more preferably self-amplifying RNA (saRNA), and polymers, in particular cationic polymers, such as polyethylenimine (PEI), poly-L-Lysin (PEL), polyvinylamine (PVA) or polyallylamine (PAA), where individual RNA molecules are present in solution. In the formulations, the RNA is preferentially present in the form of monomers, dimers, timers or oligomers, but not as aggregates comprising a large number of RNA molecules per aggregate, in particular large polyplex nanoparticles. The formulations display improved transfection efficacy and they can be used for delivery of RNA to a subject, where they have an improved dose response relationship in comparison to formulations where large aggregates in the form of polyplex nanoparticles are present.

This application relates to a method for producing cadaverine dicarboxylate (cadaverine sebacate, cadaverine undecane diate, or cadaverine dodecane diate), comprising a first step of culturing L-lysine-producing microorganisms in a medium supplemented with dicarboxylic acid in the form of diammonium dicarboxylate to obtain lysine dicarboxylate, and a second step of converting the lysine dicarboxylate to cadaverine dicarboxylate. According to this application, by carrying out the process according to the above procedure, a high-purity cadaverine dicarboxylate (cadaverine sebacate, cadaverine undecane diate, or cadaverine dodecane diate) can be obtained without ion resin exchange, decarboxylation, or distillation steps.

Method of feeding young pigs involves feeding young pigs with complete mixed feed. Wherein, isoleucine levels in the composition of mixed feed are specifically regulated by introducing synthetic isoleucine. The ratio of standardized ideal digestible (SID) isoleucine to lysine in the diet is 0.55. The specified ratio is maintained in the diets of young pigs during the nursery after weaning, from 24 to 70 days of age.